HKG:2315 Revenue

In the year 2024, Biocytogen Pharmaceuticals (Beijing) had annual revenue of 980.45M CNY with 36.76% growth. Biocytogen Pharmaceuticals (Beijing) had revenue of 569.96M in the half year ending December 31, 2024, with 87.02% growth.

Revenue

980.45M CNY

Revenue Growth

+36.76%

P/S Ratio

8.67

Revenue / Employee

877.76K CNY

Employees

1,117

Market Cap

9.05B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	980.45M	263.54M	36.76%
Dec 31, 2023	716.91M	183.03M	34.28%
Dec 31, 2022	533.88M	179.33M	50.58%
Dec 31, 2021	354.56M	101.01M	39.84%
Dec 31, 2020	253.54M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
BeOne Medicines	32.49B
Hansoh Pharmaceutical Group Company	13.05B
JD Health International	61.89B
Innovent Biologics	10.03B
WuXi Biologics	19.87B
Sino Biopharmaceutical	30.72B
CSPC Pharmaceutical Group	28.99B
Akeso	2.26B

Revenue Rankings

Biocytogen Pharmaceuticals (Beijing) News

11 days ago - Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing - Financial Post
24 days ago - Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform - Business Upturn
24 days ago - Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009) - Financial Post
6 months ago - Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors - Financial Post

More News